This recent drop highlights revived worries regarding the initial earnings dilution stemming from its Penumbra ...

Boston Scientific BSX has raised its full-year 2025 guidance following robust first-quarter results and continued momentum across key growth areas. The company now anticipates net sales to grow ...

Boston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest ...

Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY ...

John Bradley Sorenson, the EVP of $BSX, sold 6,389 shares of the company on 02-12-2025 for an estimated $671,249. We received data on the trade from a recent SEC ...

Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks presents investors with the ...

Boston Scientific Corporation BSX remains in the spotlight, with its stock currently trading close to its 52-week high. In the past six trading sessions, the stock has consistently traded above $90.00 ...

Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 7.91% on an annualized basis producing an average annual return of 20.24%. Currently, Boston Scientific has a market ...